Increased aldosterone levels can cause hypertension. Lorundrostat was designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for its production. The Launch-HTN trial ...

Lorundrostat was designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for its production. Lorundrostat has 374-fold selectivity for aldosterone-synthase inhibition ...

Increased aldosterone levels can cause hypertension. Lorundrostat was designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for its production. The Launch-HTN trial ...

Lorundrostat is specifically designed to lower aldosterone levels by targeting and inhibiting CYP11B2, the enzyme that drives its production. The study demonstrated consistent reductions in blood ...

Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has synthesized cytochrome P450 11B2, mitochondrial (CYP11B2; aldosterone synthase; ALDOS) inhibitors reported to be useful for the ...

Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has synthesized cytochrome P450 11B2, mitochondrial (CYP11B2; aldosterone synthase; ALDOS) inhibitors reported to be useful for the ...

Conclusions—Smoking and dyslipidemia are more potent risk factors for nonfatal MI in males who have the −344C allele of CYP11B2. These associations with well-established predictors of morbidity and ...

By blocking the enzyme CYP11B2, which is responsible for making aldosterone, lorundrostat directly addresses the cause of high blood pressure in these patients. The Launch-HTN trial used ...

Lorundrostat was designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for its production. Lorundrostat has 374-fold selectivity for aldosterone-synthase inhibition ...